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Introduction 
Post-transplant lymphoproliferative disorder
(PTLD) represents an abnormal lymphoid pro-
liferation  that  occurs  in  recipients  of  solid
organ or bone marrow allograft. It includes a
diverse group of diseases ranging from poly-
morphic B-cell hyperplasia to frank malignant
lymphoma.  Clinical  presentation  is  variable,
ranging from asymptomatic to generalized lym-
phadenopathy,  mononucleosis-like  syndrome,
nodal or extranodal tumors (usually gastroin-
testinal tract), systemic lymphomatous involve-
ment, and rare (less than 1% of cases) fulmi-
nant disseminated disease. PTLD is more com-
mon  in  children  than  in  adults.  Younger
patients usually present with mononucleosis-
like symptoms. We present an unusual case of
a 5-year old male who developed a widely dis-
seminated leukemic form of PTLD, involving
lymph  nodes,  tonsils,  multiple  organs,  bone
marrow,  cerebrospinal  fluid,  and  peripheral
blood. 
Case Report 
A 5-year old male, an ex-23 week premature
baby with a history of necrotizing enterocolitis
and  multiple  small  bowel  resections,  under-
went a small bowel transplant at the age of two
for short bowel syndrome. Three years later, he
presented  with  bulky  cervical  lymphadenopa-
thy,  enlarged  tonsils,  and  a  5-day  history  of
fever,  chills,  and  stridor.  Laboratory  data
revealed a lymphocytosis of 160,000. Imaging
studies showed a near-total obstruction of the
nasopharynx. A cervical lymph node excisional
biopsy, tonsillectomy, and adenoidectomy were
performed and revealed histological evidence
of post-transplant lymphoproliferative disorder.
A staging work-up demonstrated PTLD in the
supraclavicular, mediastinal, abdominal, pelvic,
and  inguinal  lymph  nodes;  peripheral  blood;
cerebrospinal  fluid;  thoracic  and  abdominal
organs; and in the bone marrow. 
Results 
H&E stained sections of the cervical lymph
node and tonsils revealed diffuse effacement of
the normal lymphoid architecture by a popula-
tion of large atypical lymphoid cells showing
enlarged nuclei and prominent nucleoli, with
brisk mitotic activity and areas of necrosis and
tingible  body  macrophages.  (Figure  1).  Flow
cytometric analysis demonstrated the neoplas-
tic cells were positive for CD19, CD20, HLA-DR,
and CD138. With immunohistochemistry stain-
ing, the large atypical cells were B cells positive
for CD20, CD79a, CD43, BCL-2, CD30, EBV-LMP
(Figure  2),  and  CD138.  Ki-67  proliferation
index was increased at 80%. 
A  prominent  T-lymphoid  background  was
also  present.  In  situ  hybridization  for  EBV-
encoded RNA (EBER) was positive. With the
patient’s  history  of  visceral  transplant  and
recently increasing EBV titers, these findings
were indicative of a monomorphic B-cell PTLD
with  features  of  an  aggressive  B-cell  lym-
phoma.  Bilateral  bone  marrow  biopsies
revealed  extensive  marrow  involvement  by
PTLD. (Figure 3). PCR analysis was positive for
monoclonal  immunoglobulin  heavy  chain
rearrangement and EBNA, leading to a diagno-
sis of EBV-associated monoclonal B-PTLD. Both
peripheral  blood  and  cerebrospinal  fluid
showed lymphocytosis with atypical lymphoid
cells. Flow cytometry demonstrated a B-cell lym-
phoproliferative disorder consistent with PTLD. 
Conclusion
PTLD is a relatively uncommon but devastat-
ing complication of immunosuppression used
to  prevent  rejection  in  transplant  patients.
Patients receiving liver-bowel or heart-lung allo-
grafts develop PTLD at the highest frequency
(5%).
1 The majority of PTLD is associated with
EBV-infection,  and  usually  occurs  within  five
years of the transplant.
2 The etiology appears to
be an EBV-induced monoclonal or, less often,
polyclonal B-cell or monoclonal T-cell prolifera-
tions in a setting of diminished T-cell immune
surveillance in an immunocompromised host.  
Conventionally,  initial  management  for  all
patients with PTLD is reduction of immunosup-
pression. If disease persists following reduction
of  immunosuppression,  alternative  therapies
are  considered,  including  local  therapy  with
radiation or surgical resection, anti-viral med-
ications, intravenous immunoglobulins, alpha-
interferon, chemotherapy, or a combination of
these.
3
Early lesions including plasmacytic hyperpla-
sia and infectious mononucleosis-like PTLD are
the most common type of PTLD in children.
4
Usually,  a  reduction  in  immunosuppression
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Figure 1. Lymph node with atypical lym-
phoid cells.
Figure 3. Extensive bone marrow involve-
ment by PTLD.
Figure 2. Atypical lymphoid cells labeled
with EBV-LMP.[Pediatric Reports 2010; 2:e6] [page 21]
leads  to  regression  of  disease  without  graft
rejection,  and  prognosis  is  excellent.
Polymorphic  and,  less  often,  monomorphic
PTLD may also regress with reduced immuno-
suppression.  However,  acute  and/or  chronic
rejection  may  ensue,  resulting  in  graft  loss
and/or death. Some cases of polymorphic PTLD
and  the  majority  of  monomorphic  PTLD  may
progress to lymphoma, requiring chemotherapy.
Several  adverse  prognostic  factors  include
multi-site disease, advanced stage, older age at
diagnosis, and late onset disease. Overall, bone
marrow allograft recipients have a higher mor-
tality rate than solid organ allograft recipients.
In  solid  organ  recipients,  PTLD  tends  to
involve lymph nodes, GI tract, lungs and, less
frequently, the CNS. Peripheral blood is rarely
involved. Children usually present with a non-
aggressive disease with early lesions including
plasmacytic hyperplasia or infectious mononu-
cleosis-like symptoms involving the oropharynx
and regional lymph nodes. Our case is remark-
able in that it is a “leukemic” form of dissemi-
nated PTLD with peripheral blood, bone mar-
row, CNS, lymph node, and extranodal involve-
ment in a 5-year old.     
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